PF-Atlas › Clinical Trials › NCT04235140
Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
LUM/IVA · Phase 3
Registry ID
NCT04235140
Phase
Phase 3
Status
Completed
Drug / intervention
LUM/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2020-02-24
About this trial
LUM/IVA is evaluated in NCT04235140, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT04235140 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.